• Refine Query
  • Source
  • Publication year
  • to
  • Language
  • 173
  • 60
  • 29
  • 13
  • 8
  • 6
  • 6
  • 6
  • 6
  • 6
  • 6
  • 6
  • 5
  • 5
  • 2
  • Tagged with
  • 351
  • 351
  • 351
  • 351
  • 141
  • 140
  • 102
  • 91
  • 67
  • 58
  • 56
  • 51
  • 50
  • 39
  • 28
  • About
  • The Global ETD Search service is a free service for researchers to find electronic theses and dissertations. This service is provided by the Networked Digital Library of Theses and Dissertations.
    Our metadata is collected from universities around the world. If you manage a university/consortium/country archive and want to be added, details can be found on the NDLTD website.
41

Expression of human insulin-like growth factor I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) in transgenic tobacco.

January 2004 (has links)
Cheung Chun Kai. / Thesis submitted in: December 2003. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2004. / Includes bibliographical references (leaves 133-146). / Abstracts in English and Chinese. / Acknowledgements --- p.ii / Abstract --- p.iv / 摘要 --- p.vii / Table of Contents --- p.ix / List of Tables --- p.xv / List of Figures --- p.xvi / List of Abbreviations --- p.xxi / Chapter Chapter 1 --- Overview --- p.1 / Chapter Chapter 2 --- Literature Review --- p.3 / Chapter 2.1 --- Historical background --- p.3 / Chapter 2.2 --- Insulin-like growth factor --- p.5 / Chapter 2.2.1 --- Structure and synthesis --- p.5 / Chapter 2.2.2 --- Physiologic role and biological actions --- p.6 / Chapter 2.3 --- Insulin-like growth factor binding protein-3 --- p.8 / Chapter 2.3.1 --- Structure and synthesis --- p.8 / Chapter 2.3.2 --- Physiologic role and biological actions --- p.8 / Chapter 2.4 --- Clinical aspects --- p.10 / Chapter 2.4.1 --- Metabolic effects of IGF-1 --- p.10 / Chapter 2.4.1.1 --- Similarities between IGF-I and insulin --- p.11 / Chapter 2.4.1.2 --- Differences between IGF-I and insulin --- p.13 / Chapter 2.4.2 --- Glucose and protein metabolism --- p.14 / Chapter 2.4.3 --- Therapeutic use of IGF-I --- p.15 / Chapter 2.4.3.1 --- Type 1 diabetes mellitus --- p.16 / Chapter 2.4.3.2 --- Type 2 diabetes mellitus --- p.17 / Chapter 2.4.4 --- Side effects --- p.19 / Chapter 2.5 --- World demands --- p.21 / Chapter 2.5.1 --- Significance of large-scale production --- p.21 / Chapter 2.5.2 --- IGF-I production --- p.21 / Chapter 2.6 --- Plants as bioreactors --- p.24 / Chapter 2.6.1 --- Medical molecular farming --- p.24 / Chapter 2.6.2 --- Advantages of plant bioreactor --- p.24 / Chapter 2.6.3 --- Commercial biopharmaceutical protein --- p.25 / Chapter 2.7 --- Tobacco expression system --- p.26 / Chapter 2.7.1 --- Tobacco model plant --- p.26 / Chapter 2.7.2 --- Transformation methods --- p.26 / Chapter 2.8 --- Hypotheses and aims of study --- p.28 / Chapter Chapter 3 --- Expression of Human IGF-I and IGFBP-3 in Transgenic Tobacco --- p.30 / Chapter 3.1 --- Introduction --- p.30 / Chapter 3.2 --- Materials and methods --- p.31 / Chapter 3.2.1 --- Chemicals --- p.31 / Chapter 3.2.2 --- Plant materials --- p.31 / Chapter 3.2.3 --- Bacterial strains --- p.32 / Chapter 3.2.4 --- Codon modification of IGF-I and IGFBP-3 cDNAs --- p.32 / Chapter 3.2.5 --- Transient assay to study IGF-I or IGFBP-3 translatability --- p.39 / Chapter 3.2.5.1 --- Construction of chimeric genes for particle bombardment --- p.39 / Chapter 3.2.5.2 --- Particle bombardment of GUS fusion constructs --- p.42 / Chapter 3.2.6 --- Construction of chimeric genes for tobacco transformation --- p.44 / Chapter 3.2.6.1 --- Construction of chimeric genes with different promoters --- p.44 / Chapter 3.2.6.1.1 --- Construction of chimeric gene with CaMV 35S promoter --- p.44 / Chapter 3.2.6.1.2 --- Construction of chimeric genes with phaseolin promoter --- p.46 / Chapter 3.2.6.2 --- Construction of fusion constructs --- p.48 / Chapter 3.2.6.2.1 --- Construction of GUS fusion constructs --- p.48 / Chapter 3.2.6.2.2 --- Construction of LRP fusion constructs --- p.51 / Chapter 3.2.6.3 --- Construction of phaseolin targeting constructs --- p.56 / Chapter 3.2.6.3.1 --- Construction of phaseolin targeting constructs without AFVY --- p.56 / Chapter 3.2.6.3.2 --- Construction of phaseolin targeting constructs with AFVY --- p.60 / Chapter 3.2.6.4 --- Cloning of chimeric genes into Agrobacterium binary vector pBI 121 --- p.64 / Chapter 3.2.7 --- Confirmation of sequencing fidelity of chimeric genes --- p.66 / Chapter 3.2.8 --- Transformation of Agrobacterium by electroporation --- p.66 / Chapter 3.2.9 --- Transformation of tobacco --- p.67 / Chapter 3.2.10 --- Selection and regeneration of transgenic tobacco --- p.67 / Chapter 3.2.11 --- GUS assay --- p.68 / Chapter 3.2.12 --- Extraction of leaf genomic DNA --- p.68 / Chapter 3.2.13 --- PCR of genomic DNA --- p.69 / Chapter 3.2.14 --- Synthesis of DIG-labeled double-stranded DNA probe --- p.69 / Chapter 3.2.15 --- Southern blot analysis --- p.70 / Chapter 3.2.16 --- Extraction of total RNA from leaves or developing seeds --- p.70 / Chapter 3.2.17 --- Northern blot analysis --- p.71 / Chapter 3.2.18 --- Extraction of total protein --- p.71 / Chapter 3.2.19 --- Tricine SDS-PAGE --- p.72 / Chapter 3.2.20 --- Western blot analysis --- p.72 / Chapter 3.2.21 --- Enterokinase digestion of fusion protein --- p.73 / Chapter Chapter 4 --- Results --- p.74 / Chapter 4.1 --- Particle bombardment for transient assay --- p.74 / Chapter 4.1.1 --- Construction of GUS fusion genes for particle bombardment --- p.74 / Chapter 4.1.2 --- Transient expression of GUS fusion genes in soybean cotyledons and tobacco leaves --- p.76 / Chapter 4.2 --- Construction of chimeric genes for tobacco transformation --- p.78 / Chapter 4.3 --- "Tobacco transformation, selection and regeneration" --- p.81 / Chapter 4.4 --- Detection of GUS activity --- p.83 / Chapter 4.5 --- Detection of transgene integration --- p.84 / Chapter 4.5.1 --- Extraction of genomic DNA and PCR --- p.84 / Chapter 4.5.2 --- Southern blot analysis --- p.88 / Chapter 4.6 --- Detection of transgene transcription --- p.92 / Chapter 4.6.1 --- Extraction of total RNA --- p.92 / Chapter 4.6.2 --- Northern blot analysis --- p.92 / Chapter 4.7 --- Detection of transgene translation --- p.99 / Chapter 4.7.1 --- Extraction of total protein and Tricine SDS-PAGE --- p.99 / Chapter 4.7.2 --- Western blot analysis --- p.102 / Chapter 4.7.3 --- Enterokinase digestion of fusion protein --- p.109 / Chapter Chapter 5 --- Discussion --- p.111 / Chapter 5.1 --- Codon modification of IGF-I and IGFBP-3 cDNAs --- p.114 / Chapter 5.2 --- Transient expression of IGF-I and IGFBP-3 cDNAs --- p.116 / Chapter 5.3 --- Fusion of IGF-I and IGFBP-3 cDNA with LRP gene --- p.118 / Chapter 5.4 --- Enterokinase digestion --- p.120 / Chapter 5.5 --- Phaseolin targeting signal --- p.122 / Chapter 5.6 --- Gene silencing --- p.124 / Chapter 5.7 --- Future perspectives --- p.128 / Chapter Chapter 6 --- Conclusion --- p.131 / References --- p.133
42

Rice as bioreactor to produce functional human insulin-like growth factor-1 (1GF-1) and insulin-like growth factor binding protein-3 (1GFBP-3). / CUHK electronic theses & dissertations collection

January 2007 (has links)
Insulin-like growth factor I (IGF-I) is a polypeptide protein hormone similar to insulin. It plays an important role in growth and anabolic effects in life. Most circulating IGF-I is bound to high-affinity insulin-like growth factor binding protein-3 (IGFBP-3), to form a complex (IGF-I/IGFBP-3) that can treat growth hormone insensitivity syndrome (GHIS) and can lower plasma glucose in diabetic patients. Its side effects can be reduced without affecting the therapeutic efficacy. Human insulin-like growth factor binding protein 3 (hIGFBP-3) alone is an anti-tumor agent. It has been shown to have anti-proliferation effect on numerous cancer cells, such as breast, prostate and liver cancers. / Our previous study has demonstrated that recombinant hIGF-I (rhIGF-I) and hIGFBP-3 (rhIGFBP-3) could be synthesized in transgenic tobacco plant. In the present study, we propose to establish an efficient bioreactor platform for mass production of hIGF-I and hIGFBP-3 in rice, as rice grain contains 8-15% of protein by dry weight. In order to enhance rhIGF-I and rhIGFBP-3 stability and yield, and to control their glycosylation, various constructs were designed and transformed into rice by Agrobacterium-mediated transformation. Protein targeting signal sequence (KDEL) was fused to direct the target proteins to specific compartments in rice grain for glycosylation in the Golgi apparatus or for stable accumulation without complex glycan processing in the endoplasmic reticulum. These expression constructs were driven by seed-specific glutelin promoter (Gt1pro). Western blot analysis showed that the rhIGF-I and rhIGFBP-3 were successfully expressed in transgenic rice grains. Biological activity of rhIGF-I was evidenced by the induction of membrane ruffling in L6 rat skeletal muscle cells, while rhIGFBP-3 was effective in inhibiting the effect of IGF-I on membrane ruffling of L6 cell. Moreover, rhIGFBP-3 was also found to inhibit the growth of human breast cancer MCF-7 cells. Biological activity results showed that the active expression levels of rhIGF-I and rhIGFBP-3 were found to be 10 ug and 7.36 ug per 1 g of rice seed respectively. These findings suggested that both rice-produced rhIGF-I and rhIGFBP-3 were biologically active. / Cheung, Chun Kai. / "September 2007." / Adviser: Peter Tong Chun Yip. / Source: Dissertation Abstracts International, Volume: 69-08, Section: B, page: 4555. / Thesis (Ph.D.)--Chinese University of Hong Kong, 2007. / Includes bibliographical references (p. 209-243). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Electronic reproduction. [Ann Arbor, MI] : ProQuest Information and Learning, [200-] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract in English and Chinese. / School code: 1307.
43

The insulin-like growth factor system - effects of circulating proteases /

Gustafsson, Sara. January 2005 (has links)
Licentiatavhandling (sammanfattning) Stockholm : Karol. inst., 2005. / Härtill 3 uppsatser.
44

Insulin and IGF-I in type 1 diabetes /

Hedman, Christina A., January 2005 (has links) (PDF)
Diss. (sammanfattning) Linköping : Univ., 2005. / Härtill 5 uppsatser.
45

Regulation of insulin-like growth factor-II in human liver /

Horn, Henrik von, January 2006 (has links)
Diss. (sammanfattning) Stockholm : Karolinska institutet, 2006. / Härtill 4 uppsatser.
46

Insulin-like growth factor I and linear growth at birth to five days in rats

Chan, Yue-sin. January 2002 (has links)
published_or_final_version / abstract / Medical Sciences / Master / Master of Medical Sciences
47

The oestrogen receptor in porcine granulosa cells

Bains, Harvinder January 2002 (has links)
No description available.
48

Screen for proteins that regulate sensitivity to inhibition of the insulin-like growth factor 1 receptor

Gao, Shan January 2012 (has links)
The type 1 insulin-like growth factor receptor (lGF-1 R) plays a significant role in tumor growth and spread, and IGF-1 R inhibitors and antibodies are now undergoing clinical testing. However, factors that regulate sensitivity to IGF-1 R inhibition remain unclear. The aim of this project is to identify proteins whose depletion regulates sensitivity to IGF-1 R inhibition, in order to design effective combination treatments to benefit patients. An IGF-1 R kinase inhibitor, AZ12253801 (provided by AstraZeneca) was able to block IGF-induced phosphorylation of IGF-1 R in DU145 prostate cancer and MCF-7 breast cancer cells, inhibited downstream signalling in DU145 cells, and also inhibited proliferation and cell survival of both cell lines. AZ12253801 was used in an unbiased siRNA screen in both cell lines, using two s'iRNA libraries (779 kinase-related Kinome and 230 DNA repair-associated siRNAs). Eight Kinome and five DNA repair-associated hits have been identified after primary and second round screens, and further validated. The strongest hit was dishevelled homolog 3 (DVL3), a member of the WNT signalling pathway, which is highly expressed in both cell lines. DVL3 silencing caused reduction in active l3-catenin and inactivated the mTOR pathway, consistent with previous studies, and did not affect IGF-1 Rand AKT activity. However, DVL3 silencing led to activation of MEK1/2-ERK1/2 in serum-starved cells and sensitized this pathway to IGF-1 stimulation, with translocation of ERK1/2 into the nucleus and increased expression of ERK1/2 target genes. A DVL PDZ domain inhibitor (DVLi) showed similar effects on active l3-catenin, mTOR signalling and ERK1/2 signalling activity. The administration of DVLi increased sensitivity to AZ12253801 in cell lines with detectable ERK1/2 activation, but not prostate cancer cells in which ERK signalling was suppressed and AKT was activated in the context of loss of functional PTEN. Furthermore, DVL3 regulated activation of ERKs by influencing signaling downstream of the IGF-1 R and upstream of RAS, and DVL3 was found in a complex with the adaptor proteins GRB2 and DAB2. GRB2 knockdown was capable of abolishing ERK1/2 activation induced by DVLi, further implicating involvement of GRB2, and DAB2 silencing sensitized to IGF-1 R inhibition, mimicking effects of DVL3 depletion. Taken together, DVL3 silencing or inhibition enhances sensitivity to IGF-1 R inhibition by negatively regulating the ERK1/2 signaling pathway. These investigations shed new light on the factors that regulate IGF signaling, and provide a rational basis for design of clinical trials of IGF-1 R inhibitors.
49

Common carp (cyprinus carpio) IGF-II: molecular cloning and expression studies.

January 2001 (has links)
Tse Chui-ling. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2001. / Includes bibliographical references (leaves 130-146). / Abstracts in English and Chinese. / Acknowledgments --- p.i / Abstract --- p.ii / 論文撮要 --- p.iii / List of Figures and Tables --- p.iv / Abbreviations --- p.vi / Table of contents --- p.vii / Chapter Chapter I --- Introduction --- p.1 / Chapter 1.1 --- Literature review --- p.1 / Chapter 1.1.1 --- An overview of IGFs --- p.3 / Chapter 1.1.2 --- Molecular biology of IGFs --- p.5 / Chapter 1.1.2.1 --- IGF-I and IGF-II genes and mRNAs --- p.5 / Chapter 1.1.2.2 --- Amino acid sequences of IGF-II --- p.8 / Chapter 1.1.2.3 --- Imprinting of IGF-II --- p.12 / Chapter 1.1.3 --- IGF distribution in tissues and body fluids --- p.14 / Chapter 1.1.3.1 --- IGF in serum --- p.14 / Chapter 1.1.3.2 --- IGF binding proteins --- p.16 / Chapter 1.1.4 --- IGF receptors --- p.19 / Chapter 1.1.4.1 --- Structures of the IGF receptors --- p.20 / Chapter 1.1.4.2 --- Ligand binding of the IGF receptors --- p.21 / Chapter 1.1.4.3 --- Signal transduction and biological response --- p.22 / Chapter 1.1.5 --- Biological effects of IGF --- p.24 / Chapter 1.1.6 --- Expression of recombinant IGF --- p.28 / Chapter 1.2 --- Rationale and Objective --- p.29 / Chapter Chapter II --- Methodology --- p.33 / Chapter 2.1 --- Design of degenerate primers --- p.33 / Chapter 2.2 --- Cloning --- p.35 / Chapter 2.2.1 --- DNA extraction from agarose gel --- p.35 / Chapter 2.2.2 --- Linearization and dephosphorylation of plasmid DNA --- p.35 / Chapter 2.2.3 --- Blunt-end ligation of amplicon with linearized plasmid --- p.36 / Chapter 2.2.4 --- T/A ligation of amplicon with linearized plasmid --- p.37 / Chapter 2.2.5 --- Sticky end ligation of foreign DNA with linearized plasmid --- p.37 / Chapter 2.2.6 --- Preparation of competent of E. coli stain DHI5α cells --- p.38 / Chapter 2.2.7 --- Transformation of plasmid vector into competent cells (heat-shock/ electroporation) --- p.39 / Chapter 2.2.8 --- "Spread single colony, PCR check clone and inoculation" --- p.40 / Chapter 2.2.9 --- Small scale alkali preparation of plasmid DNA --- p.41 / Chapter 2.2.10 --- Large scale preparation of plasmid DNA --- p.41 / Chapter 2.2.11 --- Nucleotide sequencing --- p.41 / Chapter 2.2.11.1 --- Manual sequencing --- p.41 / Chapter 2.2.11.2 --- PCR sequencing --- p.43 / Chapter 2.3 --- Northern blot --- p.45 / Chapter 2.4 --- Preparation of radio-labeled probe and hybridization of radio-labeled probe to nylon immobilized nucleic acid --- p.46 / Chapter 2.5 --- RACE --- p.48 / Chapter 2.5.1 --- Design of gene-specific primer --- p.51 / Chapter 2.5.2 --- First strand cDNA synthesis --- p.51 / Chapter 2.5.3 --- TdT tailing of cDNA --- p.52 / Chapter 2.6 --- Poly-A tract extraction --- p.53 / Chapter 2.7 --- Tissue distribution of mRNA --- p.53 / Chapter 2.7.1 --- Tissue preparation --- p.53 / Chapter 2.7.2 --- Total RNA extraction --- p.54 / Chapter 2.7.3 --- Formaldehyde agarose gel electrophoresis of RNA --- p.54 / Chapter 2.8 --- RNAse protection assay --- p.55 / Chapter 2.8.1 --- Antisense probe generation --- p.56 / Chapter 2.8.2 --- Preparation of the sample RNA --- p.58 / Chapter 2.8.3 --- Hybridization --- p.58 / Chapter 2.8.4 --- RNase digestion of hybridized probe and sample RNA --- p.59 / Chapter 2.8.5 --- Preparation of radioactive marker --- p.60 / Chapter 2.8.6 --- Separation and detection of protected fragments --- p.60 / Chapter 2.8.7 --- Data processing and statistical analysis --- p.61 / Chapter 2.9 --- Injection of GH --- p.62 / Chapter 2.10 --- Recombinant protein expression --- p.62 / Chapter 2.10.1 --- Plasmid construction --- p.62 / Chapter 2.10.2 --- Expression --- p.63 / Chapter 2.11 --- Resolution of proteins on SDS-PAGE --- p.63 / Chapter 2.12 --- Purification --- p.64 / Chapter 2.13 --- Western transfer --- p.64 / Chapter 2.14 --- Immunodetection --- p.65 / Chapter Chapter III --- Results & Discussion --- p.67 / Chapter 3.1 --- Isolation and characterization of IGF-II cDNA and its gene organization --- p.67 / Chapter 3.1.1 --- Introduction --- p.67 / Chapter 3.1.2 --- Results --- p.68 / Chapter 3.1.2.1 --- Generation of a fragment of the common carp IGF-II cDNA by PCR --- p.68 / Chapter 3.1.2.2 --- Isolation of the full length common carp IGF-II cDNA by RACE. --- p.69 / Chapter 3.1.2.3 --- Nucleotide sequence analysis --- p.74 / Chapter 3.1.2.4 --- Relationship of common carp IGF-II to common carp IGF-I and insulin --- p.78 / Chapter 3.1.2.5 --- Confirmation of the presence of IGF-II in common carp --- p.79 / Chapter 3.1.2.6 --- Multiple mRNA forms of common carp IGF-I and IGF-II --- p.80 / Chapter 3.1.2.7 --- Gene organization of the common carp IGF-II gene --- p.83 / Chapter 3.1.3 --- Discussion --- p.86 / Chapter 3.2 --- Tissue specific distribution of IGF-I and IGF-II mRNA and their hormonal regulation --- p.90 / Chapter 3.2.1 --- Introduction --- p.90 / Chapter 3.2.2 --- Results --- p.94 / Chapter 3.2.2.1 --- RNase protection assay measurement of tissue mRNA levels in juvenile and adult common carp --- p.94 / Chapter 3.2.2.2 --- Expression of IGF-II mRNA during larval development --- p.99 / Chapter 3.2.2.3 --- Effect of GH on IGF-I and IGF-II mRNA levels in brain and Hver of juvenile common carp --- p.102 / Chapter 3.2.3 --- Discussion --- p.106 / Chapter 3.3 --- Recombinant common carp IGF-II expressed in E. coli --- p.110 / Chapter 3.3.1 --- Introduction --- p.110 / Chapter 3.3.2 --- Results --- p.112 / Chapter 3.3.2.1 --- Product of recombinant common carp IGF-II --- p.112 / Chapter 3.3.2.2 --- Purification of common carp IGF-II --- p.115 / Chapter 3.3.2.3 --- Immunodetection --- p.117 / Chapter 3.3.3 --- Discussion --- p.118 / Chapter Chapter IV --- General conclusion --- p.120 / Appendix: Reagents --- p.124 / Reference list --- p.130
50

Insulin-like Growth Factor-1 Protects Skeletal Muscle Integrity From The Adverse Effects Of Angiotensin Ii In An Injury-induced Regeneration Model

January 2015 (has links)
1 / Sarah Elizabeth Galvez

Page generated in 0.087 seconds